CV Sciences, Inc. (CVSI) stock
Close on Oct 19, 2026Market cap $2.30MP/E –Yield –
CV Sciences, Inc. saw revenue fall 14.9% to $12.74M over the twelve months to Jun 30, 2026. Free cash flow was -$522.00K. At the latest close the market valued the company at $2.30M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.30M
- P/E ratio
- –
- Price to sales
- 0.18
- Price to book
- 1.46
- Dividend yield
- –
- Free cash flow yield
- -22.73%
Fundamentals
- Revenue
- $12.74M
- Net income
- -$2.01M
- EPS, diluted
- $0.00
- Free cash flow
- -$522.00K
- Book value per share
- $0.01
- Diluted shares
- 205M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.02
- Volume
- 653,640
- Average volume (20 days)
- 296,519
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CVSI | S&P 500 | Difference | CVSI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.0% | +0.6% | −20.6 pts | ||
| 3 months | -44.0% | +3.4% | −47.4 pts | ||
| Year to date | -81.8% | +13.3% | −95.0 pts | ||
| 1 year | -69.5% | +16.6% | −86.2 pts | ||
| 3 years | -72.0% | +86.4% | −158.4 pts | -34.6% | +23.1% |
| 5 years | -95.1% | +81.9% | −177.0 pts | -45.4% | +12.7% |
| 10 years | -98.4% | +318.9% | −417.2 pts | -33.8% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CV Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About CV Sciences
Pharmaceutical Preparations
CV Sciences, Inc. is a consumer wellness company that develops, manufactures, and markets herbal supplements, cannabidiol (CBD) products, and plant-based foods. Its offerings include hemp extracts, cannabinoid-free supplements, and shelf-stable plant-based protein foods marketed under brand names such as +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox. The company serves individual consumers, retailers, wholesalers, and pet owners, while also operating a business-to-business contract manufacturing service that provides custom softgel and tincture encapsulation for clients in the supplement and nutrition industry.
Company profile, executives and historyCV Sciences stock: common questions
What is CV Sciences's stock price?
CVSI closed at $0.01 on Oct 19, 2026, down 21.13% on the day.
What is CV Sciences's market cap?
CV Sciences was worth $2.30M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CVSI's P/E ratio?
CV Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does CV Sciences make?
CV Sciences reported revenue of $12.74M for the twelve months to Jun 30, 2026, down 14.9% from a year earlier.
Does CV Sciences pay a dividend?
No. CV Sciences has not paid a cash dividend over the last twelve months.
When does CV Sciences report earnings next?
CV Sciences is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CVSI stock performed over the past year?
Including dividends, CVSI returned -69.5% over the past year, against +16.6% for the S&P 500.
Who are CV Sciences's competitors?
Companies most similar to CV Sciences by business, industry and size include LIFD, BHST, ISCO, EMMA, MEHA.
See a number that looks wrong?